Wynne, Christopher John
Cole, Alexandra
Lemech, Charlotte
Wang, Guoqin
Zhang, Yu
Chen, Benchao
Wang, Max
Li, Baiyong
Xia, Michelle
Sinclair, Rodney
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
https://doi.org/10.1007/s13555-023-01010-1
Funding for this research was provided by:
Akeso Biopharma Inc
Article History
Received: 10 July 2023
Accepted: 8 August 2023
First Online: 5 September 2023
Declarations
:
: The authors declare no conflict of interest.
: The study was designed and conducted according to guidelines of Good Clinical Practice(GCP), the current Declaration of Helsinki and National Medical Product Administration (NMPA). The protocol of this study was approved by the ethics committee. An informed consent document approved by independent ethics committee was signed by the subjects or their legally authorized representative before the participant entered in the study.
: All named authors made substantial contributions to the conception or design of the work, or to the acquisition, analysis or interpretation of data. All named authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy of integrity of any part of the work are appropriately investigated and resolved and have given their approval for this version to be published. All named authors meet the international Committee of Medical Journal(ICMJE) criteria for authorship for this manuscript.